| 2026-08-12 | Press release | AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ |
| 2026-08-10 | Press release | AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing |
| 2026-08-03 | Press release | AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point |
| 2026-07-07 | Press release | AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Progra |
| 2026-06-24 | Press release | AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through K |
| 2026-06-22 | Press release | AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series |
| 2026-06-18 | Press release | AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic |
| 2026-06-15 | Press release | AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency |
| 2026-06-09 | Press release | AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules |
| 2026-06-08 | Press release | AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintato |
| 2026-06-04 | Press release | AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola |
| 2026-06-01 | Press release | AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pan |
| 2026-06-01 | Press release | PDF |
| 2026-05-27 | Press release | AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergenc |
| 2026-05-27 | Press release | PDF |
| 2026-05-20 | Press release | PDF |
| 2026-05-20 | Press release | AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement |
| 2026-05-19 | Press release | AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to Ju |
| 2026-05-19 | Press release | PDF |
| 2026-05-14 | Press release | AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic C |
| 2026-05-14 | Press release | PDF |
| 2026-05-08 | Press release | AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds |
| 2026-05-08 | Press release | PDF |
| 2026-05-07 | Press release | AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Sugg |
| 2026-05-07 | Press release | PDF |
| 2026-04-16 | Press release | AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, |
| 2026-04-16 | Press release | PDF |
| 2026-04-13 | Press release | AIM ImmunoTech Provides Routine Update on Annual Filings |
| 2026-04-13 | Press release | PDF |
| 2026-04-09 | Press release | AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event |
| 2026-04-09 | Press release | PDF |
| 2026-03-18 | Press release | AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhib |
| 2026-03-06 | Press release | AIM ImmunoTech Announces Closing of its Rights Offering |
| 2026-03-04 | Press release | AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 |
| 2026-03-02 | Press release | AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-St |
| 2026-02-27 | Press release | AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Of |
| 2026-02-25 | Press release | AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 |
| 2026-02-23 | Press release | AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the |
| 2026-02-12 | Press release | AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event |
| 2026-02-12 | Press release | CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering |